pharmaphorum

NOVEMBER 19, 2020

Because Roche has never applied for Avastin to be used in wet AMD, clinics in the US have had to choose between the peace of mind offered by the regulatory process and Lucentis’ higher price tag, or the unapproved off-label formulation of Avastin at a lower price.

FDA Approval 64

FDA Approval Marketing Drugs Clinical Development 64

pharmaphorum

DECEMBER 2, 2020

After the war, Pfizer continued to focus on industrial chemicals as much as medicines, producing the citric acid needed for the emerging soft drinks industry, fuelling brands like Coca Cola and Dr Pepper’s expansion in the 1880s. By 1868, Pfizer’s revenues had doubled since the start of the war, and their product lines had expanded greatly.

Sales 128

Sales Production Drugs Marketing 128

pharmaphorum

FEBRUARY 26, 2021

These two acquisitions enabled the company to gain a significant presence in the field of pharmaceutical medicines for the first time. But like many of its big pharma peers, it faces increased pressure on some of its biggest brands, as expiring patents pave the way for generic competition while biosimilars undercut sales of biologics.

Sales 124

Sales Production Pharma Companies Marketing 124

pharmaphorum

DECEMBER 7, 2021

Viagra (sildenafil) – originally developed by Pfizer – is now widely available as a generic and can even be bought from pharmacies over-the-counter in some countries. Sildenafil is also sold as Revatio to treat pulmonary artery hypertension (PAH).

Drugs 52

Drugs Clinical Trials Clinical Trials Scientist 52

XTalks

MARCH 22, 2023

But as patents on best sellers have been expiring over the last decade, generic competition has chiseled away at profits even if these less-expensive competitors haven’t bumped the branded medication off of the blockbuster list altogether. By nature, this change severely narrows the patient pool likely to benefit from a new treatment.

Life Science 97

Life Science Drugs FDA Approval Vaccination 97

The Pharma Data

MAY 4, 2021

Internal Medicine. In March 2021, Pfizer announced the publication of complete results from the JADE COMPARE study of its investigational oral, once-daily, Janus kinase 1 (JAK1) inhibitor in The New England Journal of Medicine (NEJM). REVENUES. . . . . . ($ in millions). First-Quarter. . 1,611. . *. *. Rare Disease.

Vaccination 40

Vaccination Vaccine Production Sales 40